October monthly recap
Editor's picks
Review the most promising opportunities from our online partnering platform, Connect, hand-picked by our team. Request an introduction connect with the asset owners, share feedback to guide their development, or follow the project to get notified of future updates. Sign up for the network here. ?
CY-101: a dual-action peptide-based cancer therapy
Biotech: Cytovation
Scientists at Cytovation have developed CY-101, a peptide-based cancer therapy that works by attacking cancer cell membranes to trigger an immune response, and by blocking a pathway that helps tumors resist treatment. It has shown promising results in early trials, and a partnership with Merck aims to boost its effectiveness when combined with the drug Keytruda. The team are seeking further investment and co-development partners.??
A low-cost and effective underwater camera?
University: University of Rhode Island?
Researchers at the University of Rhode Island have developed an underwater imaging system designed for extreme conditions. Their 3D-printed, epoxy-sealed electronics offer cost-efficiency and durability, while open-source Python software enables customization for different research purposes. It has been field tested at over 3300 meters in depth, making advanced imaging accessible to both commercial and academic sectors. The team seeks an industry partner.??
Connect Campaigns
Connect Campaigns leverage our global scientific network to address industrial R&D needs and priorities through partnerships.?The campaigns below are active, seeking the submission of research, assets, expertise, and technologies from academic groups, TTOs, and startups.
??
Non-combustion uses for asphaltenes derived from bitumen
An integrated energy company is seeking opportunities to utilize asphaltenes derived from bitumen. Approaches should deliver valuable end products with a clear path to scale for high-volume consumption. Improvements on previously identified uses of asphaltenes are also of interest.
Late-stage hospital assets for paediatric diseases
Shionogi Europe is seeking partners to advance late-stage, hospital-focused assets for paediatric disease treatment. Specifically, they are seeking therapeutics for rare or infectious diseases and critical care, focusing on small molecules and peptides.?
New solutions for skin allergy sufferers
Kenvue is seeking partners to advance novel or improved over-the-counter solutions for sufferers of atopic dermatitis, allergic/ contact dermatitis, and urticaria.
领英推荐
Antibiotic-free microbial expression and genetic systems
A world-leading animal health company is seeking partners to advance novel antibiotic-free microbial expression systems for producing biologics including recombinant proteins, peptides, antigens, and monoclonal antibodies. They are also seeking partners or technologies to support removal of AMR genes from bacterial genomes through genetic modification.?
New product
A targeted, scalable, and continuous way to activate scientific networks
Activating scientific networks relies heavily on conventional practices – asset databases that focus on late-stage research, partnering conferences that are expensive and time-bound, personal networks that are unscalable or reliance on consultants, and advisors that have limited coverage.?
Inpart’s Connect Enterprise is a new solution offering an effective way to activate the right scientific networks for your R&D needs - a dedicated platform to share your partnering needs to a vetted and network, allowing you to find leads traditional databases miss, and strengthen your reputation through consistent communication.?
New report
R&D trends and breakthrough innovations: Nanotechnology
We recently published our latest R&D trends and breakthrough innovations report, in nanotechnology.?
Gain unique insights into the most promising applications of nanotechnology, a view on the most active institutes in our network, and an exclusive R&D healthcheck from the NIA.?
Labiotech?
How an innovative, data-driven approach is revolutionizing drug discovery for solid tumors
Identifying novel targets and suitable drugs for solid tumors could lead to true breakthroughs, increasing efficacy and reducing side effects. Cancer tissue biobanks combined with a detailed knowledge of the differences between tumor and healthy tissue, and a deep understanding of tumor heterogeneity, are cornerstones for developing new treatments.
Content from Labiotech, sponsored by Indivumed Therapeutics?
Inpart is the trusted platform for scientific partnering. We provide solutions to facilitate, optimize, and track collaborations helping bring science to life.
Our online partnering network is used by over 17,000 scientists and decision-makers in industry and academia matched by their research priorities and interests.
Signup for our network to identify new research and assets seeking partners, and establish new contacts for potential and future collaborations.
Or, speak with our team about how our platforms can help optimize your alliance management, due diligence, and partnering operations.